Top-Rated StocksTop-RatedNASDAQ:DNLI Denali Therapeutics (DNLI) Stock Price, News & Analysis $13.99 -0.11 (-0.78%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Denali Therapeutics Stock (NASDAQ:DNLI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Denali Therapeutics alerts:Sign Up Key Stats Today's Range$13.83▼$14.5550-Day Range$13.04▼$16.6552-Week Range$10.57▼$33.33Volume1.75 million shsAverage Volume1.13 million shsMarket Capitalization$2.03 billionP/E RatioN/ADividend YieldN/APrice Target$33.71Consensus RatingBuy Company OverviewDenali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.Read More… Denali Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks90th Percentile Overall ScoreDNLI MarketRank™: Denali Therapeutics scored higher than 90% of companies evaluated by MarketBeat, and ranked 86th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingDenali Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.06, and is based on 14 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageDenali Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Denali Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Denali Therapeutics are expected to decrease in the coming year, from ($2.71) to ($3.03) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Denali Therapeutics is -5.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Denali Therapeutics is -5.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDenali Therapeutics has a P/B Ratio of 1.64. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Denali Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.50% of the float of Denali Therapeutics has been sold short.Short Interest Ratio / Days to CoverDenali Therapeutics has a short interest ratio ("days to cover") of 7.8.Change versus previous monthShort interest in Denali Therapeutics has recently decreased by 2.21%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDenali Therapeutics does not currently pay a dividend.Dividend GrowthDenali Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.84 Percentage of Shares Shorted9.50% of the float of Denali Therapeutics has been sold short.Short Interest Ratio / Days to CoverDenali Therapeutics has a short interest ratio ("days to cover") of 7.8.Change versus previous monthShort interest in Denali Therapeutics has recently decreased by 2.21%, indicating that investor sentiment is improving. News and Social Media2.2 / 5News Sentiment0.93 News SentimentDenali Therapeutics has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Denali Therapeutics this week, compared to 6 articles on an average week.Search Interest4 people have searched for DNLI on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Denali Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Denali Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders12.50% of the stock of Denali Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions92.92% of the stock of Denali Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Denali Therapeutics' insider trading history. Receive DNLI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Denali Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address DNLI Stock News HeadlinesDenali Therapeutics: Navigating Through Recent SetbacksJune 26, 2025 | seekingalpha.comWilliam Blair Keeps Their Buy Rating on Denali Therapeutics (DNLI)May 8, 2025 | theglobeandmail.comI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his advisors, I believed him. I believed the promise that he would finally confront the single most dangerous threat to American life. That he would fix the ticking time bomb I’ve been warning about for 15 years. But I was wrong.June 30 at 2:00 AM | Porter & Company (Ad)Denali Therapeutics price target lowered to $29 from $30 at BairdMay 8, 2025 | msn.comCompanies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In GrowthMay 8, 2025 | finance.yahoo.comDenali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter SyndromeMay 6, 2025 | globenewswire.comDenali Therapeutics upgraded to Overweight from Neutral at Cantor FitzgeraldApril 10, 2025 | markets.businessinsider.comDenali Initiates BLA Filing For Accelerated Approval Of Hunter Syndrome TreatmentApril 4, 2025 | nasdaq.comSee More Headlines DNLI Stock Analysis - Frequently Asked Questions How have DNLI shares performed this year? Denali Therapeutics' stock was trading at $20.38 at the start of the year. Since then, DNLI stock has decreased by 31.4% and is now trading at $13.99. View the best growth stocks for 2025 here. How were Denali Therapeutics' earnings last quarter? Denali Therapeutics Inc. (NASDAQ:DNLI) issued its quarterly earnings data on Tuesday, May, 6th. The company reported ($0.78) earnings per share for the quarter, missing analysts' consensus estimates of ($0.71) by $0.07. When did Denali Therapeutics IPO? Denali Therapeutics (DNLI) raised $149 million in an IPO on Friday, December 8th 2017. The company issued 8,300,000 shares at $17.00-$19.00 per share. Goldman Sachs, Morgan Stanley and J.P. Morgan served as the underwriters for the IPO and Evercore ISI was co-manager. How do I buy shares of Denali Therapeutics? Shares of DNLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Denali Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Denali Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Adobe (ADBE) and ServiceNow (NOW). Company Calendar Last Earnings5/06/2025Today6/30/2025Next Earnings (Estimated)7/30/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:DNLI CIK1714899 Webwww.denalitherapeutics.com Phone(615) 866-8548FaxN/AEmployees430Year Founded2015Price Target and Rating Average Stock Price Target$33.71 High Stock Price Target$45.00 Low Stock Price Target$24.00 Potential Upside/Downside+141.9%Consensus RatingBuy Rating Score (0-4)3.06 Research Coverage17 Analysts Profitability EPS (Most Recent Fiscal Year)($2.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$422.77 million Net MarginsN/A Pretax MarginN/A Return on Equity-35.90% Return on Assets-32.41% Debt Debt-to-Equity RatioN/A Current Ratio9.56 Quick Ratio9.56 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.53 per share Price / Book1.63Miscellaneous Outstanding Shares145,276,000Free Float127,117,000Market Cap$2.03 billion OptionableOptionable Beta1.32 Social Links 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free Report This page (NASDAQ:DNLI) was last updated on 6/30/2025 by MarketBeat.com Staff From Our PartnersAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredGold Shock (insane new prediction)World Gold Council reports: "No sign" of this catalyst slowing A whopping 73% of Americans report they're "...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Denali Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Denali Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.